Amplification and expression of EGFR and ERBB2 in Wilms tumor

Cancer Genetics and Cytogenetics

Volumn 194, Issue 2, 2009, Pages 88-95

  Vasei, Mohammad ^a   Modjtahedi, Helmout ^b   Ale booyeh, Oreineb ^a   Mosallaei, Ahmad ^c   Kajbafzadeh, Abdol Mohammad ^d   Shahriari, Mehdi ^c   Ghaderi, Abbas Ali ^e   Soleymanpour, Hossein ^a   Kosari, Farid ^f   Moch, Holger ^g   Sauter, Guido ^h  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 3; MYC PROTEIN; PROTEIN MDM2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; RAF PROTEIN; RAF1 PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ADOLESCENT; ARTICLE; BLASTEMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADOLESCENT; ANIMALS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; GENES, ERBB-1; GENES, ERBB-2; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; WILMS TUMOR;

ALIAS;

EID: 70349209107     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.06.003     Document Type: Article

References (50)

1. Gommersall L.M., Arya M., Mushtaq I., and Duffy P. Current challenges in Wilms' tumor management. Nat Clin Pract Oncol 2 (2005) 298-304
2. Pritchard-Jones K. Controversies and advances in the management of Wilms' tumour. Arch Dis Child 87 (2002) 241-244
3. Nicholson R.I., Gee J.M.W., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 Suppl. 4 (2001) S9-S15
4. Navolanic P.M., Steelman L.S., and McCubrey J.A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 22 (2003) 237-252
5. Rubin I., and Yarden Y. The basic biology of HER2. Ann Oncol 12 Suppl. 1 (2001) S3-S8
6. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., and Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230 (1985) 1132-1139
7. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 (2003) 2787-2799
8. Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev 24 (2005) 129-146
9. Norum J. The cost effectiveness issue of adjuvant trastuzumab in early breast cancer. Expert Opin Pharmacother 7 (2006) 1617-1625
10. Hortobagyi G.N. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 28 6 Suppl. 18 (2001) 43-47
11. Ghanem M.A., Van Der Kwast T.H., Den Hollander J.C., Sudaryo M.K., Mathoera R.B., Van den Heuvel M.M., Noordzij M.A., Nijman R.J., and van Steenbrugge G.J. Expression and prognostic value of epidermal growth factor receptor-transforming growth factor-α, and c-erb B-2 in nephroblastoma. Cancer 92 (2001) 3120-3129
12. Pinthus J.H., Fridman E., Dekel B., Goldberg I., Kaufman-Francis K., Eshhar Z., Harmelin A., Rechavi G., Mor O., Ramon J., and Mor Y. ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor. J Urol 172 (2004) 1644-1648
13. Salem M., Kinoshita Y., Tajiri T., Souzaki R., Tatsuta K., Higashi M., Izaki T., Kohashi K., Tsuneyoshi M., and Taguchi T. Association between the HER2 expression and histological differentiation in Wilms tumor. Pediatr Surg Int 22 (2006) 891-896
14. Dei Tos A.P., and Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. Eur J Cancer 41 (2005) 1383-1392
15. Hicks D.G., and Tubbs R.R. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol 36 (2005) 250-261
16. Ross J.S., and Fletcher J. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112 1 Suppl. 1 (1999) S53-S67
17. Schnitt S.J., and Jacobs T.W. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 116 (2001) 806-810
18. Argani P., and Beckwith B.J. Renal neoplasms of childhood. In: Mills S.E., Carter D., Grenson J.K., Oberman H.A., Reuter V., and Stoler M.H. (Eds). Sternberg's diagnostic surgical pathology. 4th ed (2004), Lippincott Williams & Wilkins, Philadelphia 2001-2032
19. Moch H., Sauter G., Gasser T.C., Bubendorf L., Richter J., Presti Jr. J.C., Waldman F.M., and Mihatsch M.J. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol 184 (1998) 424-429
20. Neal D.E., Sharples L., Smith K., Fennelly J., Hall R.R., and Harris A.L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65 (1990) 1619-1625
21. Cybulsky A.V., Goodyer P.R., and McTavish A.J. Epidermal growth factor receptor activation in developing rat kidney. Am J Physiol 267 (1994) F428-F436
22. Sakurai H., Tsukamoto T., and Kjelsberg C.A. EGF receptor ligands are a large fraction of in vitro branching morphogenesis secreted by embryonic kidney. Am J Physiol 273 (1997) F463-F472
23. Goodyer P.R., Mulligan L., and Goodyer C.G. Expression of growth-related genes in human fetal kidney. Am J Kidney Dis 17 (1991) 608-610
24. Press M.F., Hung G., Godolphin W., and Slamon D.J. Sensitivity of HER-2/ neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54 (1994) 2771-2777
25. Singleton T.P., Niehans G.A., Gu F., Litz C.E., Hagen K., Qiu Q., Kiang D.T., and Strickler J.G. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23 (1992) 1141-1150
26. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., Brown A., Yothers G., Anderson S., Smith R., Wickerham D.L., and Wolmark N. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94 (2002) 852-854
27. De Potter C.R., Quatacker J., Maertens G., Van Daele S., Pauwels C., Verhofstede C., Eechaute W., and Roels H. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44 (1989) 969-974
28. Dowsett M., Bartlett J., Ellis I.O., Salter J., Hills M., Mallon E., Watters A.D., Cooke T., Paish C., Wencyk P.M., and Pinder S.E. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199 (2003) 418-423
29. Press M.F., Slamon D.J., Flom K.J., Park J., Zhou J.Y., and Bernstein L. Evaluation of HER-2/ neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
30. Tapia C., Glatz K., Novotny H., Lugli A., Horcic M., Seemayer C.A., Tornillo L., Terracciano L., Spichtin H., Mirlacher M., Simon R., and Sauter G. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 20 (2007) 192-198
31. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
32. Mass R.D., Press M.F., Anderson S., Cobleigh M.A., Vogel C.L., Dybdal N., Leiberman G., and Slamon D.J. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6 (2005) 240-246
33. Hammock L., Lewis M., Phillips C., and Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol 34 (2003) 1043-1047
34. Tedesco K.L., Thor A.D., Johnson D.H., Shyr Y., Blum K.A., Goldstein L.J., Gradishar W.J., Nicholson B.P., Merkel D.E., Murrey D., Edgerton S., and Sledge Jr. G.W. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22 (2004) 1071-1077
35. Cunningham M.P., Essapen S., Thomas H., Green M., Lovell D.P., Topham C., Marks C., and Modjtahedi H. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28 (2006) 329-335
36. Essapen S., Thomas H., Green M., De Vries C., Cook M.G., Marks C., Topham C., and Modjtahedi H. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 24 (2004) 241-248
37. Navarro S., Giraudo P., Karseladze A.I., Smirnov A., Petrovichev N., Savelov N., Alvarado-Cabrero I., and Llombart-Bosch A. Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. Anticancer Res 27 (2007) 2457-2463
38. Kilpatrick S.E., Geisinger K.R., King T.S., Sciarrotta J., Ward W.G., Gold S.H., and Bos G.D. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14 (2001) 1277-1283
39. Lambropoulou M., Stefanou D., Alexiadis G., Tamiolakis D., Tripsianis G., Chatzaki E., Vandoros G.P., Kiziridou A., Papadopoulou E., and Papadopoulos N. Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie 30 (2007) 495-500
40. Gumurdulu D., Uguz A., Erdogan S., Tuncer I., and Demircan O. Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: an immunohistochemical study. Endocr Res 29 (2003) 465-472
41. Horvai A.E., Li L., Xu Z., Kramer M.J., Jablons D.M., and Treseler P.A. Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. Arch Pathol Lab Med 127 (2003) 465-469
42. Lahoti C., Thorner P., Malkin D., and Yeger H. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Am J Pathol 148 (1996) 1577-1589
43. Cheah P.L., Looi L.M., and Chan L.L. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia. Histopathology 28 (1996) 49-54
44. Govender D., Harilal P., and Hadley G.P. p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer 77 (1998) 314-318
45. Bardeesy N., Beckwith J.B., and Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 55 (1995) 215-219
46. Momand J., Zambetti G.P., and Olson D.C. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 (1992) 1237-1245
47. Ramachandran C., Melnick S.J., Escalon E., Jhabvala P., Khatib Z., Alamo A., and Smith S. Expression of apoptosis, cell proliferation, and drug resistance genes in pediatric Wilms' tumors. Anticancer Res 20 (2000) 3759-3765
48. Re G.G., Willingham M.C., el Bahtimi R., Brownlee N.A., Hazen-Martin D.J., and Garvin A.J. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor. Mod Pathol 10 (1997) 129-136
49. Marcus V.A., Madlensky L., Gryfe R., Kim H., So K., Millar A., Temple L.K., Hsieh E., Hiruki T., Narod S., Bapat B.V., Gallinger S., and Redston M. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 23 (1999) 1248-1255
50. Cunningham M.P., Essapen S., Thomas H., Green M., Lovell D.P., Topham C., Marks C., and Modjtahedi H. Coexpression, prognostic significance and predictive value of the EGFR, EGFRvIII and phosphorylated EGFR. in colorectal cancer. Int J Oncol 27 (2005) 317-325